CEAPRO INC.
TSX VENTURE : CZO

CEAPRO INC.

July 31, 2007 10:53 ET

Ceapro Diabetes Screening Patent Granted

EDMONTON, July 31 - Ceapro Inc. (TSX VENTURE:CZO) has received Notice of Allowance from the Canadian Trademarks Office for its proprietary diabetes testing wafer meal, CeaProve®.

Said company CEO, Mark Redmond, "The approval of our CeaProve® patent allows us to take commercial advantage of the technology we've developed over the past several years. Follow-on patent applications are pending which would give Ceapro an exclusive market position on the diabetes test product until 2021."

The CeaProve® test meal is a more accurate and better tolerated alternative to the existing tests for diabetes and pre-diabetes. It consists of six highly calibrated wafers equivalent to a balanced meal of carbohydrate, protein and fat. Two major clinical studies have shown that a significant advantage of this test over the traditional glucose drink is due to its oat starch component, which results in a blood glucose response that is more physiological and thus reproducible. As well, there are little to no side effects as there is no major rise and crash of blood glucose.

With epidemic increases in the incidences of Diabetes - much of which can be avoided - early and regular testing for glucose intolerance just became easier and more pleasant. Manufacturing of the CeaProve® test kits is now underway and commercial rollout is expected in the early fall.

About Ceapro Inc.

Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc. and Ceapro Bioenergy Inc. are wholly owned subsidiaries of Ceapro Inc., which is a Canadian growth-stage biotechnology company. Our primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will be applying our technology to become an active participant in the bioenergy sector. We have also introduced health and wellness services employing our CeaProve® diagnostic technology. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit www.ceapro.com.

The TSX has neither approved nor disapproved of the information contained herein - This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact Information

  • Dr. Mark Redmond
    President and CEO
    Ceapro Inc.
    Telephone (Edmonton): (780) 421-4555

    Nicole Blanchard
    B.Sc., B.Comm. Managing Partner
    Sun International Communications
    Telephone (Montreal): (450) 627-6600